PMC:7600245 / 24383-24579
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T95 | 138-146 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T332 | 11-22 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T333 | 69-80 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T334 | 82-100 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T335 | 105-116 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T176 | 0-196 | Sentence | denotes | Currently, favipiravir is being studied alone or in combination with tocilizumab, hydroxychloroquine, or oseltamivir for the treatment of COVID-19 in more than 23 clinical trials across the world. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 657 | 11-22 | Chemical | denotes | favipiravir | MESH:C462182 |
| 658 | 69-80 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 659 | 82-100 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 660 | 105-116 | Chemical | denotes | oseltamivir | MESH:D053139 |
| 667 | 138-146 | Disease | denotes | COVID-19 | MESH:C000657245 |